These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 17343842)

  • 1. Omapatrilat enhances adrenomedullin's reduction of cardiomyocyte cell death.
    Rabkin SW; Klassen SS
    Eur J Pharmacol; 2007 May; 562(3):174-82. PubMed ID: 17343842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palmitate-induced NO production has a dual action to reduce cell death through NO and accentuate cell death through peroxynitrite formation.
    Rabkin SW; Klassen SS
    Prostaglandins Leukot Essent Fatty Acids; 2008 Feb; 78(2):147-55. PubMed ID: 18191557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic effect of combined treatment with omapatrilat and adrenomedullin on the progression of heart failure in rats.
    Nishikimi T; Mori Y; Ishimura K; Ishikawa Y; Koshikawa S; Akimoto K; Minamino N; Kangawa K; Matsuoka H
    Am J Hypertens; 2006 Oct; 19(10):1039-48. PubMed ID: 17027825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanical stretch induces mitochondria-dependent apoptosis in neonatal rat cardiomyocytes and G2/M accumulation in cardiac fibroblasts.
    Liao XD; Wang XH; Jin HJ; Chen LY; Chen Q
    Cell Res; 2004 Feb; 14(1):16-26. PubMed ID: 15040886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of a vasopeptidase inhibitor vs. an angiotensin converting enzyme inhibitor on cardiomyocyte apoptosis in rats with heart failure.
    Lapointe N; Tsoporis JN; Parker TG; Blais C; Adam A; Rouleau D; Slaughter G; Clément R; Deschepper CE; Rouleau JL
    Mol Cell Biochem; 2003 Dec; 254(1-2):235-45. PubMed ID: 14674703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients.
    Campese VM; Lasseter KC; Ferrario CM; Smith WB; Ruddy MC; Grim CE; Smith RD; Vargas R; Habashy MF; Vesterqvist O; Delaney CL; Liao WC
    Hypertension; 2001 Dec; 38(6):1342-8. PubMed ID: 11751715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic protective effect of cyclosporin A and rotenone against hypoxia-reoxygenation in cardiomyocytes.
    Teixeira G; Abrial M; Portier K; Chiari P; Couture-Lepetit E; Tourneur Y; Ovize M; Gharib A
    J Mol Cell Cardiol; 2013 Mar; 56():55-62. PubMed ID: 23238221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial effects with ceramide-induced cardiac apoptosis are different from those of palmitate.
    Kong JY; Rabkin SW
    Arch Biochem Biophys; 2003 Apr; 412(2):196-206. PubMed ID: 12667483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heart failure and vasopeptidase inhibitors].
    Bareiss P; Ohlmann P; Roul G
    Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):51-3. PubMed ID: 11933558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of complex III of the mitochondrial electron transport chain is essential for early heart muscle cell differentiation.
    Spitkovsky D; Sasse P; Kolossov E; Böttinger C; Fleischmann BK; Hescheler J; Wiesner RJ
    FASEB J; 2004 Aug; 18(11):1300-2. PubMed ID: 15180963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway.
    Danz ED; Skramsted J; Henry N; Bennett JA; Keller RS
    Free Radic Biol Med; 2009 Jun; 46(12):1589-97. PubMed ID: 19303434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of protein synthesis and statin-induced cardiomyocyte cell death.
    Rabkin SW; Lodha P; Kong JY
    Cardiovasc Toxicol; 2007; 7(1):1-9. PubMed ID: 17646677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omapatrilat: a unique new agent for the treatment of cardiovascular disease.
    Nawarskas JJ; Anderson JR
    Heart Dis; 2000; 2(3):266-74. PubMed ID: 11728268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
    Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
    J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of the HMG-CoA reductase inhibitor lovastatin and nitric oxide in cardiomyocyte cell death.
    Rabkin SW; Tsang MY
    Pharmacology; 2008; 82(1):74-82. PubMed ID: 18504415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat.
    Loch D; Hoey A; Brown L
    Clin Exp Hypertens; 2006 Jul; 28(5):475-88. PubMed ID: 16820344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Inhibition of the Renin-Angiotensin System and Neprilysin Positively Influences Complex Mitochondrial Adaptations in Progressive Experimental Heart Failure.
    Grois L; Hupf J; Reinders J; Schröder J; Dietl A; Schmid PM; Jungbauer C; Resch M; Maier LS; Luchner A; Birner C
    PLoS One; 2017; 12(1):e0169743. PubMed ID: 28076404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective pharmacotherapy against oxidative injury: alternative utility of an ATP-sensitive potassium channel opener.
    Ozcan C; Terzic A; Bienengraeber M
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):411-8. PubMed ID: 18049309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Domoic acid impairment of cardiac energetics.
    Vranyac-Tramoundanas A; Harrison JC; Clarkson AN; Kapoor M; Winburn IC; Kerr DS; Sammut IA
    Toxicol Sci; 2008 Oct; 105(2):395-407. PubMed ID: 18596025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.